A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Phase 3 Active not recruiting 516 enrolled Eli Lilly and Company Incyte Corporation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Timeline

Start: 2019-05-24
Primary completion: 2022-04-24
Completion: 2026-05

Publications

Wollenberg A, Ikeda M, Chu CY, Eichenfield LF, Seyger MMB, Prakash A, Angle R, Zhu D, Pontes M, Paller AS. Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years. J Dermatolog Treat. 2024 Dec;35(1):2411834. doi: 10.1080/09546634.2024.2411834. Epub 2024 Nov 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Baricitinib	Small molecule	0.5 mg	Oral
Subject	Baricitinib	Small molecule	1 mg	Oral
Subject	Baricitinib	Small molecule	2 mg	Oral
Subject	Baricitinib	Small molecule	4 mg	Oral

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Summary

Timeline

Publications

Drugs

Indications